Scientists find 95 genetic variants associated with heart disease risk factor

An international team of scientists has identified 95 genetic variants associated with high blood cholesterol and triglyceride levels which are major risk factors for coronary heart disease. The study, published in the journal Nature and funded in part by the EU, could lead to novel ways of preventing and treating heart disease.

Coronary heart disease is a leading cause of death worldwide. Abnormal levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C, or 'bad' cholesterol), high-density lipoprotein cholesterol (HDL-C) and triglycerides are all known to be major risk factors for heart disease and represent important drug targets.

In their paper, the scientists describe how they carried out a genome-wide association study (GWAS), scanning the genomes of 100,000 people of European descent and looking for changes in the genetic material that are associated with changes in lipid levels.

"Although blood concentrations of cholesterol and triglycerides have long between known as risk factors for cardiovascular disease, the extent to which genetics contributes to those concentrations and just how alterations in the underlying genes leads to the development of disease has been incredibly difficult to piece together," explained Dr Sekar Kathiresan of Massachusetts General Hospital in the US.

The researchers' analyses uncovered 95 genetic variants, 59 of which were previously unknown. According to the team, taken together the 95 variants 'explain 10%-12% of the total variance (representing 25%-30% of the genetic variance'.

Many of the variants are located in genes known to be linked to lipid levels and heart disease. "Closer scrutiny of the gene loci revealed genetic variants which we know offer a molecular target for cholesterol-lowering drugs," commented Professor Thomas Meitinger of the German Research Center for Environmental Health.

The scientists also scanned the genomes of thousands of people of East Asian, south Asian and African American descent. This revealed that the majority of the variants are shared across diverse ethnic groups.

"The new findings point us to specific genetic signposts that allow us to understand more fully why many people from all walks of life have abnormal levels of cholesterol and other blood lipids that lead to heart disease," said Christopher O'Donnell of the National Institutes of Health (NIH) in the US. "What's really exciting about this work is that we are moving from discovery to understanding brand-new information about how genes alter the lipids that contribute to heart disease."

As well as shedding light on the genetic causes of abnormal lipid levels, and, by extension, heart disease risk, the study validates the use of GWAS involving ever larger numbers of people. Previous studies of the genetic factors behind high lipid levels involved 20,000 people, and some had suggested that carrying out larger studies would result in no new variants or variants whose effect is so small as to be of negligible interest from a biological or clinical point of view.

"It is often argued that large-scale meta-analyses with more than 100,000 test subjects have little significance for the biology of complex diseases," said Professor H.-Erich Wichmann of the German Research Center for Environmental Health. "Our study impressively refutes this assertion. On the contrary, some of the newly discovered gene loci have clear biological and clinical relevance."

EU support for the work came from several projects. The ENGAGE (European network for genetic and genomic epidemiology) project is financed through the Health Theme of the Seventh Framework Programme (FP7). INGENIOUS HYPERCARE (Integrated genomics, clinical research and care in hypertension), DIABESITY (Novel molecular drug targets for obesity and type 2 diabetes) and EUROSPAN (European special populations research network: quantifying and harnessing genetic variation for gene discovery) are all funded under the 'Life sciences, genomics and biotechnology for health' Thematic area of the Sixth Framework Programme (FP6). Finally, the GENOMEUTWIN (Genome-wide analyses of European twin and population cohorts to identify genes in common diseases) project was supported under the 'Quality of life and management of the living resources' programme of the EU's Fifth Framework Programme (FP5).

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Japan becomes the first country to approve Roche's…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of a...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

FDA approves Amgen and Allergan's KANJINTITM (tras…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved ind...

Vitamin D may not help your heart

While previous research has suggested a link between low levels of vitamin D in the blood and an increased risk of cardiovascular disease, a new Michigan State University...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

Researchers identify enzyme that suppresses immune…

Immunotherapies have transformed cancer care, but their successes have been limited for reasons that are both complex and perplexing. In breast cancer especially, only a ...